OrbiMed Advisors LLC 的 Form 4/A 修正申報
修正Enliven Therapeutics, Inc.（ELVN），2021/7/23 申報
- 申報編號
- 0000947871-21-000797
- 申報時間
- 2021/7/23 17:30 ET
- 交易日
- 2021/7/16
- 申報延遲
- 7 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2021/7/16
這份申報列了 1 筆非衍生性交易。公開市場買進合計 $1,000 萬。交易後 7 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | 董事、持股 10% 以上大股東 |
| OrbiMed Capital GP VII LLCCIK 0001760648 | 董事、持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/7/16 | Common Stock | P買進取得 | +1,666,666 | $6.00 | +$9,999,996 | 4,199,068 | 間接 | 重複申報 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
These shares of the Issuer's common stock ("Shares") were purchased in the Company's underwritten public offering. The previously reported acquisition of these Shares was inadvertently attributed to OrbiMed Partners Master Fund Limited.
- F2
The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
- F3
This report on Form 4 is filed by OrbiMed Advisors and GP VII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons, or David Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
備註
This Amendment is being filed solely to correct the information regarding the ownership form and nature of indirect beneficial ownership for the previously reported transaction.